anti-CD33 CAR-NK cells is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at PersonGen BioTherapeutics (Suzhou) Co., Ltd., with a possible patent signal linked through modality_match. Manual review is still required.
Target: CD33
Cell type: NK_CELL
Indications: Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With Maturation, Acute Myeloid Leukemia Without Maturation, ANLL
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Institution: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase: Phase1
Status: Unknown
Trial count: 1
Active trials: 0
First posted: October 25, 2016
Last updated: December 6, 2016
IP signal: Possible
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT02944162